Pharmaceutical Intermediates Market
Pharmaceutical Intermediates Market: Investments in Manufacturing to Ascend: Global Industry Analysis 2014 – 2018 and Opportunity Assessment 2019 – 2029
- 2019-04-26
- REP-GB-4515
- 54 Tables
- 185 Figures
- 275 pages
-
Press Release:
Pharmaceutical Intermediates Market Structure Analysis
Pharmaceutical Intermediates – Increased Care Seeking Rates and The Need for Generics
Incessant rise of chronic ailments vis-à-vis growing elder demographic has grown on the need for branded, generics as well as branded generics drugs, prompting pharmaceutical intermediates manufacturers to boost production capacities. The search for care has been increasingly palpable worldwide, fuelling the requirement for generics, specialty active pharmaceutical ingredients (API's) and quality drugs, in turn favouring sales of pharmaceutical intermediates.
Top 3 Factors Shaping the Pharmaceutical Intermediates Market
Increasing Production expected to drive the Pharmaceutical Intermediates market
Increasing demand of various pharmaceutical intermediates and APIs due to increasing production of the final drug formulation is expected to fuel the growth of the market. Globally, various manufacturing companies from the pharmaceutical as well as biopharmaceutical industries are focusing on improving their geographical product footprint. Manufacturers are focusing enhancing their product reach through various distribution channels in different countries across the world which is resulting in increasing production capacity. E.g. in January 2019, Fujifilm plans to boost its overall production capacity by expanding its production facility at North Carolina. During 2015-2017, there were more than 130 mergers and acquisitions in the pharma industry, which involved contract manufacturing organisations with operations in APIs and pharmaceutical intermediates.
Increasing Prevalence of Chronic Diseases is expected to drive the Pharmaceutical Intermediates market
The rapidly increasing prevalence of chronic diseases and the growth of the aging population across the world are among factors that are expected to increase the need for drug formulations for the management of chronic diseases. For example, according to the World Health Organization (WHO), the prevalence of diabetes has surged from 108.0 million in 1980 to 422.0 million in 2014, and the number is rising rapidly. According to the World Health Organization (WHO), the prevalence of chronic diseases is expected to increase by 57.0% by 2020, which indicates that a significant percentage of population is suffering from chronic diseases.
Increasing Investments in manufacturing expected to fuel growth in pharmaceutical intermediates market
Leading pharmaceutical companies in pharmaceutical intermediates market have announced their intentions to invest in manufacturing facilities due to various reasons such as to enhance the production capacity of pharmaceutical intermediates, reduce corporate tax rate (due to recent tax reforms in the U.S.), and to increase their global footprints as well as their presence in emerging markets. For example, in July 2018, Pfizer announced its plan to invest around US$ 465.0 million to build a sterile injectable plant in Portage, Michigan. This step is a part of its announcement that it had made earlier in 2018 about its plans to invest around US$ 5.0 billion in a U.S.-based capital project due to the recent corporate tax reforms in the country.
Pharmaceutical Intermediates Market Structure Analysis
- The global Pharmaceutical Intermediates market is categorised by small independent companies.
- Some of the prominent companies in the Pharmaceutical Intermediates market include Chiracon GmbH, BASF SE, Cambrex Corporation, etc. Most of the companies are focusing on the increasing their product portfolio offering by offering different types pharmaceutical intermediates
- The pharmaceutical intermediates market is fragmented market and majority of the manufacturing companies located in the East Asia and South Asia due to lower production cost as compared to regions such as Europe and North America
Market Set to Grow 1.5X between 2019 and 2029
Innovative strategies and work practices of the industry in helping care setting expand their remedial offerings continue to augur well for the pharmaceutical intermediates landscape. While patent expiries remain key development enablers, clinical studies on new therapeutic measures for various ailments are driving advancements in pharmaceutical intermediates.
Stakeholders Vie to Tap Opportune Potential of Emerging Markets
Stakeholders continue to uptake the relatively greater prevalence of chronic ailments and the need for generic drugs and personalized treatment in emerging markets. East Asia continues to lead the pharmaceutical intermediates landscape, with sales growing at a relatively higher rate.
* This data is only a representation. Actual data may vary and will be available in report.
-
2014
-
2018
-
2022
-
2028
The Broader Perspective
Pharmaceutical intermediates manufacturers are taking effective measures to address shortages of generic drugs. In addition, mergers and acquisitions remain a pivotal growth strategy of pharmaceutical intermediates manufacturers, which includes contract manufacturing organizations involved in APIs.
Bulk drug intermediates remain the top-selling variant, with over 60% shares
Customer intermediates sales are expected to grow at a higher rate
Adoption of chemical intermediates is expected to remain relatively low
Generic drug intermediates remain the most lucrative category, accounting for over 70% sales
Gains from branded drug intermediates will remain sluggish, owing to their high cost and complexities in manufacturing
Pharmaceutical intermediates sales in the production of analgesics remain strong, estimated to hold over one-third share
Cardiovascular drugs are also expected account for significant market shares
Sales in production of oral antidiabetic drugs will grow at a promising rate
CMOs/CROs continue to lead the pharmaceutical intermediates landscape, with nearly two-third shares
Biotech & pharma companies also account for notable shares of the market
Demand is expected to remain sluggish in research laboratories
How Growth will Unfold
CMOs/CROs are expected to account for leading shares of the pharmaceutical intermediates market, as these pose a huge demand in biopharmaceutical contract manufacturing and are used as essential ingredients in medicinal chemistry and custom synthesis. Growth rate sales in research laboratories is expected to be similar to those in CMOs/CROs, however revenues will remain sluggish. Demand for pharmaceutical intermediates in biotech & pharma companies will also remain significant.
CMOs/CROs | Research Laboratories | Biotech & pharma companies
* This data is only a representation. Actual data may vary and will be available in report.
Click Here To Know How The Growth Will UnfoldCustom Market Research Services
FMI offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.
Overview
Pharmaceutical Intermediates Market: Global Industry Analysis 2014–2018 and Forecast 2019–2029
A recent market study published by FMI “Pharmaceutical Intermediates Market: Global Industry Analysis 2014–2018 and Forecast 2019–2029” offers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historic as well as current growth parameters of the pharmaceutical intermediates market, the growth prospects of the market are obtained with maximum precision.
Pharmaceutical Intermediates Market Taxonomy
The global pharmaceutical intermediates market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach in front of the reader.
By Product Type
- Chemical Intermediates
- Bulk Drug Intermediates
- Chiral Intermediates
- Achiral Intermediates
- Custom Intermediates
By Category
- Branded Drugs
- Generic Drugs
By Application
- Analgesics
- Anti-Infective Drugs
- Cardiovascular Drugs
- Oral Antidiabetic Drugs
- Antimicrobial Drugs
- Others
By End User
- Biotechnology and Pharmaceutical Companies
- Research Laboratories
- Contract Manufacturing Organizations / Contract Research Organizations
By Region
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- MEA
What's Included
The report commences with the executive summary of the pharmaceutical intermediates market, which includes a summary of the key findings and key statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the pharmaceutical intermediates market.
Readers can find the detailed taxonomy and the definition of the pharmaceutical intermediates market in this chapter, which will help them understand the basic information about the pharmaceutical intermediates market. This section also highlights the inclusions and exclusions, which helps the reader understand the scope of pharmaceutical intermediates market report.
The report provides country wise as well as regional expenditure on health that are expected to impact the market growth significantly during the forecast period.
This section explain the global market value analysis and forecast for the pharmaceutical intermediates market between the forecast periods of 2013-2027 is highlights in this section. This chapter includes the detailed analysis of the historical pharmaceutical intermediates market along with an opportunity analysis of the future. Readers can also find the absolute opportunity for the current year (2018 – 2019), and an incremental opportunity for the forecast period (2018 – 2019).
The report provides key market trends that are expected to impact the market growth significantly during the forecast period. Detailed industry trends are provided in this section, along with key market development or product innovations.
This chapter explains the key macro-economic factors that are expected to influence the growth of the pharmaceutical intermediates market over the forecast period. Along with macroeconomic factors, this section also highlights the opportunity analysis for the pharmaceutical intermediates market. This chapter also highlights the key market dynamics of the pharmaceutical intermediates market, which include the drivers, restraints and trends. Moreover, readers will understand the key trends followed by the leading manufacturers in the pharmaceutical intermediates market.
Based on product type, the pharmaceutical intermediates market is segmented into Chemical Intermediates, Bulk Drug Intermediates and Custom Intermediates. Readers can find information about the key trends and developments in the pharmaceutical intermediates market and market attractiveness analysis based on the product type.
Based on Application the pharmaceutical intermediates market is segmented into Analgesics, Anti-Infective Drugs, Cardiovascular Drugs, Oral Antidiabetic Drugs, Antimicrobial Drugs and Others. In this chapter, readers can find information about the key trends and developments in the pharmaceutical intermediates market and market attractiveness analysis based on indication.
This chapter provides details about the pharmaceutical intermediates market on the basis of end user, and has been classified into Biotechnology & Pharmaceutical Companies, Research Laboratories, CMOs / CROs. In this chapter, readers can understand the market attractive analysis based on end user.
This chapter explains how the pharmaceutical intermediates market will grow across various geographic regions, such as North America, Latin America, Europe, East Asia, South Asia, Oceania, the Middle East & Africa (MEA)
This chapter includes a detailed analysis of the growth of the North America North America, along with a country-wise assessment that includes the U.S. and Canada.
Readers can find detailed information about several factors, such as the pricing analysis, which are impacting the growth of the Latin America. This chapter also includes the growth prospects of the pharmaceutical intermediates market in the leading LATAM countries such as Brazil, Mexico, and the Rest of Latin America.
Important growth prospects of the pharmaceutical intermediates market based on its end users in several countries, such as Germany, the UK, France, Spain, Italy, Russia and the Rest of Europe, are included in this chapter.
India, Indonesia, Thailand, Malaysia are the leading countries in the South Asia region that are the prime subjects of assessment to obtain the growth prospects of the South Asia pharmaceutical intermediates market in this chapter. Readers can find detailed information about the growth parameters of the South Asia pharmaceutical intermediates market during the period 2019–2029.
This chapter highlights the growth of the pharmaceutical intermediates market in the East Asia by focusing on China, Japan and South Korea. This section also helps readers understand the key factors that are responsible for the growth of the pharmaceutical intermediates market in East Asia.
In this chapter, Australia and New Zealand are among the leading countries in the Oceania region, which are the prime subjects of assessment to obtain the growth prospects of the Oceania pharmaceutical intermediates market.
This chapter provides information about how the pharmaceutical intermediates market will grow in the major countries in the MEA region, such as GCC Countries, South Africa, Turkey, Northern Africa and the rest of MEA, during the forecast period 2019 - 2029.
In this chapter, readers can find a detailed information about the tier analysis and market concentration of the key players in the pharmaceutical intermediates market along with their market presence analysis by region and product portfolio.
In this chapter, readers can find a comprehensive list of all the leading stakeholders in the pharmaceutical intermediates market, along with detailed information about each company, which includes the company overview, revenue shares, strategic overview, and recent company developments. Some of the market players featured in the report are Chiracon GmbH, Aceto Corporation, Midas Pharma GmbH, Codexis, Lianhetech, BASF SE, Vertellus Holdings LLC, Sanofi S.A., A. R. Life Sciences Private Limited, Dishman Group, Chemcon Speciality Chemicals Pvt. Ltd, Dextra Laboratories Ltd, Dextra Laboratories Ltd, Eastar Industries, Pfizer Inc., Bristol-Myers Squibb Company, Arkema Group, Interchem and Cambrex Corporation
This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the pharmaceutical intermediates market report.
This chapter helps readers understand the research methodology followed to obtain the various conclusions as well as important qualitative and quantitative information about the pharmaceutical intermediates market.
How the research was conducted?
Primary Research
- C - Level Executives
- Marketing Directors
- Sales Heads
- Portfolio Managers
- Purchasing Managers
- Medical Officers
- Drug Development Heads
- Strategy Advisors
- R&D Managers
- Product Manufacturers
- Distributors
- Pharmacists / Pharmacy Benefit Managers
- Hospital Purchasing Departments
- Physicians / Nursing Managers
- Industry Experts
- Current Market Dynamics and Challenges
- Market Characteristics
- Market Performance and Growth Quadrants
- Competition Structure and Market Structure
- Strategic Growth Initiatives
- Disease Patterns, Treatment and Prescription Patterns
- Regulatory and Reimbursement Landscape
- Products in Pipeline and Clinical Development
- Near-term and Long-term Market Growth Prospects
- Market Segment Splits and Authenticity
- Opinions on Market Projections and Validity of Assumptions
- Current Market Dynamics and Challenges
- Market Characteristics
- Market Performance and Growth Quadrants
- Competition Structure and Market Structure
- Strategic Growth Initiatives
- Product Adoption, Installed Base, Replacement Cycles, Refurbishment
- Regulatory Landscape
- Products in Pipeline and Clinical Development
- Near-term and Long-term Market Growth Prospects
- Market Segment Splits and Authenticity
- Opinions on Market Projections and Validity of Assumptions
Secondary Research
- Industry Magazines
- Factiva
- Company Press Releases
- Annual Reports and Investor Presentations
- Active Pharmaceutical Ingredients Committee
- Indian Drug Manufacturers' Association
- Government of Canada
- Peer-reviewed Journals
- Government Websites and Publications
- Trade Websites
- Clinical Trial Registries
- Country-specific Regulatory Authorities
World Bank, WHO, IMF, OECD
Primary Interview Splits
Pharmaceutical Intermediates Market Reports - Table of Contents
22. Assumptions and Acronyms Used
23. Research Methodology
To Learn More About our Comprehensive Perspective on Pharmaceutical Intermediates Market,
Get in touch
Harish Tiwari
Global Head - Business Development
Pranay Mhaisekar
Client Partner - Global Business Development
Our Clients
CASE STUDIES
See how our work makes an impact.
At FMI, we design strategies that are adaptive, impactful, and implementable.